Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

China — National Medical Products Administration

Tracked across 35 events · 249 articles · First seen Apr 08, 2026 · Last active Sep 16, 2026

Sentiment
5
Attention
6
Events
35
Relationships
6
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 30
Regulatory
China's China — National Medical Products Administration approved and issued the world's first product standard for brain-computer interface (BCI) medical devices that use artificial intelligence to process electroencephalogram (EEG) data. The standard, which takes effect…
Impact: The NMPA approved and issued the world's first AI BCI medical device standard, positioning itself as the leading global regulator in this emerging field.
Sep 14, 2026 · 6 articles
6 0
Regulatory
Impact: The China — National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for Lerociclib, which is a crucial regulatory step for the drug's potential approval and availability in China.
Jun 26, 2026 · 8 articles
6 0
Regulatory
Impact: The China — National Medical Products Administration granted conditional approval for ORPATHYS (savolitinib) for the treatment of gastric cancer, enabling its commercialization in China.
Jul 02, 2026 · 6 articles
4 0
Business
Impact: The China — National Medical Products Administration (NMPA) of China accepted the Investigational New Drug (IND) application for HBM7004, allowing Harbour BioMed to advance its drug towards clinical evaluation in China.
Jun 10, 2026 · 7 articles
4 0
Tech
Impact: The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.
Jun 10, 2026 · 8 articles
4 0
Business
Impact: The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.
Jun 12, 2026 · 7 articles
4 0
Regulatory
Impact: The NMPA, through its CDE, granted the BTD, demonstrating its role in facilitating the development of innovative therapies in China. This action reflects the regulatory environment's support for novel cancer treatments.
Aug 03, 2026 · 6 articles
4 0
Regulatory
Impact: The NMPA is the regulatory authority reviewing the NDA. Its approval decision will determine market access for NCX 470 in China.
Aug 10, 2026 · 6 articles
4 0
Tech
Impact: The China — National Medical Products Administration accepted the New Drug Application for fanregratinib and granted it priority review, indicating a potential expedited path to market approval in China.
Jun 24, 2026 · 6 articles
6 40
Tech
Impact: The NMPA granted commercial approval to NEO, enabling the first commercial BCI implant and setting a regulatory precedent that may influence future approvals in China.
Jul 06, 2026 · 10 articles
2 50
Business
Impact: Regulatory body granting approvals for 11 new products, facilitating domestic portfolio expansion and market competitiveness.
Jul 20, 2026 · 7 articles
1 0
Business
Frost & Sullivan published the Blue Book on the Current Status and Future Trends of the Chinese Radiofrequency-Based Medical Aesthetic Devices Industry in September 2026. The report analyzes the industry chain, favorable policies, technological evolution,…
Impact: The NMPA's tightened RF device rules, including the Class III registration mandate effective April 2026, reshape the competitive landscape by raising compliance costs and squeezing smaller manufacturers.
Sep 15, 2026 · 6 articles
2 0
Business
Impact: NMPA approved the IND application for ATG-201 Phase I study in China, enabling clinical development in the country.
Jul 13, 2026 · 7 articles
2 10
Business
Impact: The NMPA's record drug approvals and regulatory reforms create a favorable environment for innovative drug development, indirectly supporting demand for VivoSim's services.
Jul 21, 2026 · 6 articles
3 0
Tech
Impact: The NMPA, through its CDE, granted the clinical trial notice, enabling the trial to proceed.
Jul 27, 2026 · 6 articles
4 0
Business
Impact: The NMPA approved senaparib in China in January 2025, enabling its commercialization there. This approval is foundational to the drug's global development.
Jul 31, 2026 · 8 articles
4 0
Business
Impact: The China — National Medical Products Administration accepted the new drug application for roconkibart in December 2025, indicating progress in the regulatory approval process for the drug.
Jul 01, 2026 · 8 articles
6 0
Tech
Impact: The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.
May 21, 2026 · 9 articles
4 0
Tech
Impact: The China — National Medical Products Administration (NMPA) of China approved golidocitinib in June 2024 for r/r PTCL, indicating regulatory progress for one of Dizal Pharmaceutical's key assets.
May 31, 2026 · 6 articles
6 0
Tech
Impact: The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.
May 30, 2026 · 14 articles
6 0
Tech
Impact: The China — National Medical Products Administration's Center for Drug Evaluation granted BRII-179 and elebsiran Breakthrough Therapy Designation, and Brii Biosciences has reached preliminary alignment with them regarding a potential registrational study for ENRICH.
Jul 03, 2026 · 7 articles
1 0
Tech
Impact: NMPA Class III certification is a regulatory milestone for HAIRO in China.
Jul 10, 2026 · 6 articles
2 0
Business
Impact: Regulatory body that accepted NDA for JS001sc and approved sNDA for TUOYI combination; approvals support Junshi's pipeline.
Aug 26, 2026 · 8 articles
2 30
Business
Impact: Co-published a report on DCT industry practice with Tigermed.
Jul 20, 2026 · 6 articles
4 0
Business
Impact: Chinese regulator that approved Sentire, enabling its use in China.
Sep 01, 2026 · 15 articles
4 0
Regulatory
Alebund Pharmaceuticals announced that the U.S. United States — Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease for the treatment of IgA nephropathy…
Impact: The NMPA is relevant as Alebund's other pipeline candidates are under its review, but this event specifically concerns the FDA.
Jul 20, 2026 · 6 articles
4 0
Tech
Impact: The China — National Medical Products Administration is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in China, indicating the drug's established regulatory status.
Jul 01, 2026 · 6 articles
4 0
Tech
Impact: China's China — National Medical Products Administration previously approved REDEMPLO (plozasiran), further solidifying its international market approvals.
May 26, 2026 · 6 articles
4 0
Business
Impact: The China — National Medical Products Administration approved CardioACC's ICE system in 2025, indicating regulatory acceptance of the technology.
Jun 03, 2026 · 6 articles
1 0
Business
On August 4, 2026, at the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Event held at Jing An Shangri-La in Shanghai, Frost & Sullivan awarded PackGene Biotech…
Impact: The NMPA is referenced as the Chinese agency that granted IND approvals to PackGene's partners, highlighting the company's regulatory success in China.
Sep 11, 2026 · 6 articles
+ 5 more events View on Dashboard
American Society of Clinical Oncology ↔ China — National Medical Products Administration
American Society of Clinical Oncology ↔ China — National Medical Products Administration
United States — Food and Drug Administration ↔ China — National Medical Products Administration
United States — Food and Drug Administration ↔ China — National Medical Products Administration
China ↔ China — National Medical Products Administration
China ↔ China — National Medical Products Administration
ERGEN INTELLIGENCE
Track China — National Medical Products Administration live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.